<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01757418</url>
  </required_header>
  <id_info>
    <org_study_id>FD-R-005341-01</org_study_id>
    <secondary_id>FD-R-005341-01</secondary_id>
    <nct_id>NCT01757418</nct_id>
    <nct_alias>NCT00644865</nct_alias>
  </id_info>
  <brief_title>Intravenous Gammaglobulin for Sickle Cell Pain Crises</brief_title>
  <official_title>Phase 1-2 Trial of Gamunex (Intravenous Gammaglobulin) for Sickle Cell Acute Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Einstein College of Medicine, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Albert Einstein College of Medicine, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether intravenous immune globulin is safe and
      effective in the acute treatment of pain crises in sickle cell disease.

      Funding Source: Food and Drug Administration (FDA), Office of Orphan Products Development
      (OOPD)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomized to a single dose of IVIG versus normal saline placebo during an
      uncomplicated pain crisis. Length of VOC and other secondary endpoints will be monitored.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to end of vaso-occlusive crisis</measure>
    <time_frame>Number of days from start of study drug infusion to end of crisis, average 4 days and maximum 30days</time_frame>
    <description>Time to end of vaso-occlusive crisis as measured from start of study drug infusion to end of VOC end of VOC defined as 12 hours from the last dose of parenteral opioid analgesia for the treatment of VOC prior to hospital discharge</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total opioid use in equivalent of mg of IV morphine</measure>
    <time_frame>From study drug infusion to end of crisis, average 4 days and maximum 30days</time_frame>
    <description>End of VOC end of VOC defined as 12 hours from the last dose of parenteral opioid analgesia for the treatment of VOC prior to hospital discharge</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">94</enrollment>
  <condition>Sickle Cell Disease</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Immune Globulin Intravenous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IVIG used in the trial is the GAMUNEX brand, at doses up through 800 mg/kg in Phase 1 and at 400mg/kg in Phase 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>An equivalent volume (weight-based)of normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immune Globulin Intravenous</intervention_name>
    <description>A single dose of intravenous immune globulin or saline placebo administered within 24 hours of hospital presentation. The maximum dose in Phase I was 800 mg/kg. The dose for Phase II is 400mg/kg.</description>
    <arm_group_label>Immune Globulin Intravenous</arm_group_label>
    <other_name>GAMUNEX (Talecris Biotherapeutics)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>A single dose of normal saline administered within 24 hours of hospital admission for uncomplicated pain crisis.</description>
    <arm_group_label>Normal saline</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented diagnosis of sickle cell disease (SS or S-β thalassemia genotype)

          -  Age 12-65 years for Phase 1, 8-21 years for Phase 2

          -  Uncomplicated acute pain episode requiring hospital admission and parenteral narcotics

        Exclusion Criteria:

          -  Increased stroke risk as assessed by transcranial Doppler or magnetic resonance
             imaging (all subjects undergo testing)

          -  Concomitant acute process, including fever &gt; 38.5° C with clinical suspicion of
             infection

          -  Increased ALT &gt; 2X ULN

          -  Serum creatinine ≥1.3 mg/dL, &gt;300 mg/dL protein in spot urinalysis, or known condition
             associated with renal dysfunction

          -  Hb &gt; 10 g/dL and Hct &gt; 30%

          -  Hb&lt; 5 g/dl

          -  Known IgA deficiency or known allergy to gamma globulin

          -  Pregnancy or breastfeeding

          -  Vaccination with a live attenuated virus in the preceding 6 weeks

          -  Documented history of illicit (eg. heroin, cocaine) drug abuse or drug-seeking
             behavior

          -  Current participation in another investigational drug study

          -  Current treatment with chronic transfusion

          -  Prior thromboses or current estrogen use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deepa G Manwani, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein College of Medicine, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Deepa G Manwani, M.D</last_name>
    <phone>718-741-2342</phone>
    <email>dmanwani@montefiore.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karen Ireland</last_name>
    <phone>718-741-2401</phone>
    <email>kireland@montefiore.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>The Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deepa G Manwani, MD</last_name>
      <phone>718-741-2342</phone>
      <email>dmanwani@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Deepa G Manwani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Chang J, Shi PA, Chiang EY, Frenette PS. Intravenous immunoglobulins reverse acute vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion. Blood. 2008 Jan 15;111(2):915-23. Epub 2007 Oct 11.</citation>
    <PMID>17932253</PMID>
  </reference>
  <reference>
    <citation>Turhan A, Jenab P, Bruhns P, Ravetch JV, Coller BS, Frenette PS. Intravenous immune globulin prevents venular vaso-occlusion in sickle cell mice by inhibiting leukocyte adhesion and the interactions between sickle erythrocytes and adherent leukocytes. Blood. 2004 Mar 15;103(6):2397-400. Epub 2003 Nov 20.</citation>
    <PMID>14630831</PMID>
  </reference>
  <results_reference>
    <citation>Shi PA, Manwani D, Olowokure O, Nandi V. Serial assessment of laser Doppler flow during acute pain crises in sickle cell disease. Blood Cells Mol Dis. 2014 Dec;53(4):277-82. doi: 10.1016/j.bcmd.2014.04.001. Epub 2014 May 21.</citation>
    <PMID>24857171</PMID>
  </results_reference>
  <results_reference>
    <citation>Manwani D, Frenette PS. Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies. Blood. 2013 Dec 5;122(24):3892-8. doi: 10.1182/blood-2013-05-498311. Epub 2013 Sep 19.</citation>
    <PMID>24052549</PMID>
  </results_reference>
  <results_reference>
    <citation>Manwani D, Chen G, Carullo V, Serban S, Olowokure O, Jang J, Huggins M, Cohen HW, Billett H, Atweh GF, Frenette PS, Shi PA. Single-dose intravenous gammaglobulin can stabilize neutrophil Mac-1 activation in sickle cell pain crisis. Am J Hematol. 2015 May;90(5):381-5. doi: 10.1002/ajh.23956. Epub 2015 Apr 1.</citation>
    <PMID>25616042</PMID>
  </results_reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2012</study_first_submitted>
  <study_first_submitted_qc>December 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2012</study_first_posted>
  <last_update_submitted>September 20, 2017</last_update_submitted>
  <last_update_submitted_qc>September 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Albert Einstein College of Medicine, Inc.</investigator_affiliation>
    <investigator_full_name>Deepa Manwani</investigator_full_name>
    <investigator_title>Director, Sickle Cell Disease Program, Children's Hospital at Montefiore</investigator_title>
  </responsible_party>
  <keyword>Sickle Cell Disease</keyword>
  <keyword>Pain</keyword>
  <keyword>Immune Globulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

